Tuesday
10:30 - 11:00
Networking Hub

Expanding knowledge on GLP-1RAs in cardiometabolic care

Industry Meet the Expert Session

Filip Knop (Denmark)
Analysing the current role of GLP-1RAs’ cardiovascular effects: an endocrinologist’s perspective
Subodh Verma (Canada)
Exploring the future role of GLP-1RAs’ cardiovascular effects: a cardiologist’s perspective
Filip Knop (Denmark), Subodh Verma (Canada)
Discussion/Q&A

Disclaimer: Oral Semaglutide has been studied in a phase 3 clinical trial programme

Hosted by: